CD8A and neoplasm: cGAMP@vEVs promoted tumor-specific CD8+ T-cell expansion, enhanced cytotoxic T-lymphocyte (CTL) infiltration, and established a self-sustaining antitumor immune cycle, effectively inhibiting tumor growth, metastasis, and recurrence [174].